Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scope test could sharpen lung cancer staging, spare patients unnecessary radiation

NCT ID NCT01786590

Diagnosis Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a minimally invasive procedure called EBUS-TBNA is more accurate than standard CT/PET scans for checking if lung cancer has spread to lymph nodes in the chest. The goal is to better select patients for a precise type of radiation therapy (SBRT). About 150 adults with early-stage non-small cell lung cancer who cannot have surgery will undergo EBUS-TBNA before their radiation treatment. The results could help doctors make more informed treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EBUS-TBNA (a minimally invasive procedure using a thin, flexible tube with an ultrasound probe to sample lymph nodes)
What this could lead to
If EBUS-TBNA proves more accurate than CT/PET scans, it could help doctors better decide who is eligible for SBRT, potentially improving outcomes for patients who cannot have surgery.
What could go wrong
This is a diagnostic accuracy study, not a treatment trial. Even if EBUS-TBNA is more accurate, it may not directly improve survival or quality of life. The procedure itself carries small risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Feb 2013

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or older 2. Patients with confirmed lung cancer who require EBUS-TBNA as part of their staging investigations of the mediastinum and hilum prior to SBRT 3. Performance status score (WHO/ECOG) of 0-2. 4. Cytological or histological proof of non-small cell cancer 5. Stage T1-2 disease, with no evidence of distant metastasis 6. Patients are screened by both computed tomography (CT) and positron emission tomography (PET) 7. Medically inoperable for surgical resection 8. Patients who refused surgery Exclusion Criteria: 1. Patients who are deemed on clinical grounds not to be medically fit for a bronchoscopy 2. Active systemic, pulmonary, or pericardial infection 3. Patients who are pregnant or lactating 4. Patients with plans to receive conventional radiotherapy, chemotherapy, biological therapy, vaccine therapy, or surgery as treatment (except at disease progression). 5. Inability to give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Toronto General Hospital

    RECRUITING

    Toronto, Ontario, M5G 1L7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.